UZ Leuven

In modern healthcare, clinical innovation walks a tightrope between scientific ambition and meaningful patient benefit. Nowhere is this balance more evident than in ophthalmology, where new technologies and techniques can reshape vision and lives, but only when rigorously tested and responsibly implemented. As an ophthalmic surgeon and clinical researcher, I see this equation play out daily: how do we pursue progress without compromising safety, efficacy and cost-effectiveness?

Clinical research is at the heart of this conversation: structured, evidence-driven, and grounded in patient outcomes. Whether assessing the long-term benefits of premium intraocular lenses or evaluating novel intraoperative devices like the vast array of MIGS (minimally invasive glaucoma surgery), each decision must be guided by both data and clinical intuition. That’s where ophthalmology excels: the science is precise, the interventions are immediate and the impact is often life-changing.

Yet, with every new device or drug comes a risk/reward calculation. In a randomized controlled trial setting, the protocol offers structure, but variability is the rule in daily practice. Surgical success isn't just about surgical skill; it's about patient selection, perioperative support, device availability and real-time adaptability. That's why, even with promising data, innovations must be introduced with caution, collaboration and a deep understanding of their limitations.

“Every new device or drug requires careful risk-benefit analysis, not just in trials, but in daily practice where variability demands adaptability, collaboration and deep clinical understanding.”

Stakeholders - surgeons, hospital administrators, medical device companies and of course, patients - must align on what constitutes value. Is it a clinical outcome? Patient satisfaction? Cost reduction? Or long-term durability of treatment? In my experience, the answer is yes to all and finding the ideal balance between these elements. Value in ophthalmology is multifactorial, as in many other disciplines and the best outcomes arise when research and real-world practice speak the same language.

My work is guided by knowledge and driven by care. Rigorous research and surgical excellence, combined with patient-centered care, lead to better, smarter decisions.

Whether leading studies on micro-invasive glaucoma surgery or refining patient pathways for cataract treatment, my role as clinician-researcher is to help bridge that gap.

Ultimately, successful innovation in ophthalmology isn’t about adopting every new trend. It’s about identifying what works, for whom and under which conditions and then building the infrastructure to deliver it consistently and safely. In this field, the best way forward is not always the fastest. But with a steady hand, sound evidence and a clear vision, we move toward better sight and better care for all.